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T1.R cells can be generated and appear safe to infuse at
evaluated doses after AHCT in patients with PCM.Table
UPN Age Sex Disease;
Status pre
T1.R
T1.R dose
(x106/kg)
Disease
Status post
T1.R
F/U
post
T1.R
(days)
2 36 F l chain;
refractory;
CR
0.1 PD at d180 347
3 58 F l chain;
recurrent;
VGPR
3.0 PD at d28 187
5 41 F IgG l;
refractory;
SD
0.5 VGPR 257
6 66 F IgG l;
refractory;
PR
1.0 Continuing
PR
221
7 36 F IgG l;
refractory;
VGPR
5.0 Continuing
VGPR
137
8 62 F IgG l,
refractory;
PR
5.0 Continuing
PR
39
9 71 M IgG k, high-
risk; VGPR
5.0 CR 102
10 36 M IgA k, high-
risk; CR
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Insulin-Like Growth Factor 1 Mitigates Hematopoietic
Toxicity After Lethal Total Body Irradiation
Dunhua Zhou, Divino Deoliveira, Yubin Kang, Seung S. Choi,
Nelson J. Chao, Benny J. Chen. Duke University Medical Center,
Durham, NC
We have previously demonstrated that mitigation of
lethal irradiation by growth hormone is associated with
an increase of insulin-like growth factor 1 (IGF-1) level
in blood, suggesting that IGF-1 may be able to mitigate
against lethal irradiation. In this study, we tested this
possibility directly. BALB/c mice ﬁrst received 7.5 Gy of
total body radiation. Within one hour after irradiation,
the mice were then treated with IGF-1 at a dose of 100
mg/dose, i.v., once a day for 5 consecutive days. In the
saline control group, 2 out of 20 mice (10%) survived
more than 100 days after irradiation. By contrast, 8 out
of 20 mice (40%) in the IGF-1-treated group survived
more than 100 days after irradiation (P < 0.01). A single
dose of IGF-1 (500 mg) given within one hour after
irradiation was as effective as the 5-day dose. IGF-1
remained effective when the treatment was delayed for
at least up to 6 hours post irradiation. Moreover, the
radio-protective effect of IGF-1 was still evident when
higher dose of radiation (8.5 Gy, LD100/30) was used.Similar effects were also observed in a second strain of
mice (C57BL/6). Because hematopoietic system is most
sensitive to total body irradiation, we next sought to
determine the effects of IGF-1 on hematopoietic recovery.
Compared with the saline control group, treatment with
IGF-1 signiﬁcantly accelerated the recovery of both
platelets and red cells in blood in irradiated (7.5 Gy)
BALB/c mice when measured at day +14 post irradiation.
Numbers of total bone marrow cells as well as hemato-
poietic stem cells and progenitors per femur were
signiﬁcantly increased in IGF-1-treated mice compared
with the control group. Using ﬂow cytometric analysis
and a novel single cell assay, we demonstrated that IGF-1
protected both hematopoietic stem cells and progenitors
from radiation-induced apoptosis and cell death. Using
an in vitro culture system, we also demonstrated that
IGF-1 was able to facilitate the proliferation and differ-
entiation of non-irradiated and irradiated hematopoietic
progenitors but not stem cells. These data indicate that
IGF-1 mitigates against lethal irradiation through pro-
tecting hematopoietic stem/progenitor cells from radia-
tion-induced apoptosis and also through enhancing
proliferation and differentiation of surviving hematopoi-
etic progenitor cells.POSTER SESSION 1: IMMUNE RECONSTITUTION173
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Lawrence Lum7, Voravit Ratanatharathorn 8, Joseph Uberti 9.
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Transplant, Wayne State University/Karmanos Cancer Center,
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Higher absolute lymphocyte count at day 30 (ALC 30)
after allogeniec hematopoietic stem cell transplant (HSCT)
has been associatedwith better overall survival (OS). This has
largely been evaluated in small retrospective studies with
cyclosposrine and methotrexate for graft vs. host disease
(GVHD) prophylaxis. ALC 30 and its impact on patient (pt)
outcomes after tacrolimus (Tac) and mycophenolate mofetil
(MMF) is largely unknown.
We retrospectively evaluated a cohort of 414 consecu-
tive pts between January 2005 and June 2010 at Karmanos
Cancer Center. Patients with GVHD or death before day 30
post transplant were excluded from the analysis (N ¼33).
We performed a multivariate logistic regression analysis to
determine donor/recipient predictors of ALC 30. Cox
proportional hazard models were used to assess the
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listed in the table below. All analyses were adjusted for
donor/recipient age, sex, CMV status, HLA mismatch,
CD34+ cells, regimen intensity and relapse risk.
There were 191 pts in the sibling donor (SD) group and
190 pts in the unrelated donor (UD) group respectively.
The median age of pts and donors in the SD group was
older (P < .05). Pts in UD group received a higher median
of CD 34+cell dose (7.31 vs.5.63 x 106/kg P  .0001).
Median follow up of surviving pts in both groups was 58.3
months. More pts had ALC 30>400x 106 (75 vs. 65% P ¼
.025) and more pts survived (47 vs.36%P ¼ .038) in the SD
group. Factors associated with lower ALC 30 were: higher
donor age, HLA mismatch, lower recipient age, and lower
CD34 cell dose.
Lower ALC 30 (400x 106/L) was associated with lower
OS, and increased non relapse mortality (NRM) for the whole
cohort as well as for the SD and UD groups separately. Lower
ALC 30 was associated with more severe aGVHD (III-IV) in
the UD group. Lower ALC 30 was associated with more CMV
reactivation and a trend towards more aGVHD in the SD
group.
Conclusion: In this large retrospective study using Tac/MMF
for GVHD prophylaxis ALC 30 400 x 106/L was associated
with worse OS, increased NRM and aGVHD.Hazard Ratios of ALC 30 with various event outcomes
Combined Related Unrelated
Mortality
HR 2.29*** 2.58*** 2.23**
CI 1.68-3.13 1.61-4.13 1.44-3.46
NRM
HR 3.03*** 3.19*** 3.1***
CI 2.08-4.43 1.75-5.80 1.84-5.23
aGVHD (II-IV)
HR 1.47* 1.64 1.43
CI 1.06-2.03 0.99-2.72 0.9-2.28
aGVHD (III-IV)
HR 1.97** 1.9 2.19**
CI 1.31-2.97 0.96-3.75 1.27-3.77
cGVHD
HR 1.01 0.83 1.02
CI 0.7-1.45 0.47-1.47 0.62-1.69
CMV
HR 1.13 1.99* 0.6
CI 0.71-1.81 1.05-3.75 0.27-1.29
Relapse
HR 1.196 1.4 1.03
CI 0.69-2.06 0.65-2.99 0.45-2.34
* P-value < .05.
** P-value < .01.
*** P-value < .001.174
Lymphocyte Count Above 300 X 106/Ml 90 Days Post
Transplant Predicts Better Overall Survival After
Alemtuzumab for Unrelated Donor Stem Cell Transplant
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Introduction: Lymphocyte recovery after T cell depleted
allogeneic stem cell transplant (allo-HCT) is delayed for at
least 6-9 months, particularly after alemtuzumab (AL)
administration. Most studies predominantly involving
matched sibling donors and T cell replete allo-HCT have
shown that early lymphocyte recovery by day 30 is associ-
ated with better OS and EFS. Impact of absolute lymphocyte
count (ALC) after AL based allo-HCT using unrelated donors
(UD) is unknown.
Methods: We retrospectively evaluated 30 consecutive
patients (pts) who underwent allo-HCT from UDs at
Markey Cancer Center between January 2010 and May
2012. The primary end point of the study was to evaluate
the impact of ALC on transplant outcomes and assess any
predictors of higher ALC. Cox proportional hazards model
was used for time to event analysis and Odds Ratios were
calculated using logistic regression to evaluate for
predictors for ALC  300 at day 90. AL dose used was 60
mg (20 mg daily x 3 days). Low relapse risk was deﬁned
as AML and ALL in CR1, MDS with less than 10% blasts,
CLL/NHL/HL with PR and or <5 cm lymphadenopathy and
CML in chronic phase.
Results: Median age of the pts was 53.5 yrs (20-67).
Patients had AML (12), MDS (4), ALL (5), CLL (4), CML (2)
NHL (1), Hodgkins disease (1) and Aplastic Anemia (1). All
Pretransplant conditioning included alemtuzumab plus
Cyclophosphamide (Cy) TBI for 9 pts, Busulfan (Bu)/Cy for
8 pts and ﬂudarabine (Flu)/Melphalan (Mel) for 13 pts.
Seventeen pts had female donors, and 15 pts had donors
seropositive for CMV. Source of stem cells was bone
marrow (BM) for 16 pts and peripherally mobilized stem
cells (PBSCs) for 14 pts. Median CD 34+ cells infused were
4.05 x 106 cells/kg (0.83-12.98). Twenty four pts had high
relapse risk.
At day 90 ALC <300 x 106/ml was associated with higher
mortality (HR¼4.65, P ¼ .03). In our study, ALC 90 was not
associated with GVHD, NRM, CMV reactivation or relapse.
ALC 90 >300 x 106/ml was also not associated with donor's
sex, CMV status, pt's age, sex, CMV status, CD 34 cells infused,
relapse risk, HLA mismatch, source of stem cells or type of
conditioning regimen.
After a median follow up of 431 days (118-909), 16
patients are alive. Causes of deathwere GVHD (6), relapse (2),
graft failure (2), infection (2), VOD (1) and hemorrhage (1).
Five pts have relapsed. Cumulative incidence of aGVHD (II-
IV) was 36.7%, cGVHD (mild, moderate) 13.3% and CMV
reactivation (46.7%).
Conclusion: AL is associated with delayed recovery of ALC
post allo-HCT. ALC 90  300 x 106/ml was associated with
four fold higher hazard of death after AL as compared to
patients with ALC 90 > 300 x 106/ml at any given time.
Further studies are needed to conﬁrm our preliminary
ﬁndings, to elucidate factors associated with higher ALC90,
and ultimately to test proposed interventions to improve
ALC90 after allo-HCT.
